International journal of cancer
No relevant pharmacokinetic interaction between the KRAS G12C inhibitor sotorasib and the direct oral anticoagulant rivaroxaban in healthy subjects.
Esther M Hollander, Alessandra I G Buma, Jenneke Leentjens, Paddy K C Janssen, Michel M van den Heuvel, David M Burger, Berber Piet, Rob Ter Heine
Published: 202610.1002/ijc.70326
Abstract
Cancer patients have an increased risk of thromboembolic events. Consequently, anticoagulants such as rivaroxaban are often prescribed. With the increasing use of targeted therapies, there is a growing concern about potential drug-drug interactions,…
Preview only. Read the full abstract at the source